Growing interest in alternative meat market
Manufacturers are keen to get involved in the alternative meat market. Investors and incubators are pushing forward start-ups.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2185 entries already.
Entries by Thomas Gabrielczyk
Upscaling in the race to cultured meat
A first wave of cultured meat companies is pushing forward. European start-ups such as Mosa Meat and Peace of Meat are part of the game.
S-Protein: Glycosylation pattern revealed
British researchers have deciphered the glycosylation pattern of the viral spike protein of SARS-CoV-2 laying the foundation for vaccine development.
Newron terminates sarizotan development in Rett syndrome
Newron Pharmaceuticals S.p.A.s Sarizotan failed to meet efficacy endpoints in the Phase III STARS study.
Roche gets FDA okay for COVID-19 antibody test
Roche Diagnostics has received FDA Emergency use approval for its highly specific Elecsys antibody test.
European Biotechnology Guide 2020 goes digital
Additional to the print edition the European Biotechnology Science & Industry Guide 2020 is available digital in the App Store and at Google Play. Download the free BIOCOM app on smartphone, tablet or laptop and have the complete edition in one hand.
Phages as a promising alternative to antibiotics
Austrian Phagomed wants to close a Series A financing in 2020. The start-up is working on phage-based treatments as a new alternative to antibiotics.
Bone Therapeutics bags €11m
Belgian Bone Therapeutics SA has secured €11m to foster development of its late stage pipeline candidates.
Cevec launches ELEVECTA platform
Cevec Pharmaceuticals GmbH has launched a new, scalable production platform for AAV gene therapy vectors.
Artes enters COVID-19 vaccine race
German vaccine developer ARTES Biotechnology GmbH will develop a COVID-19 subunit vaccine based on virus-like particles (VLP), which include two proteins of SARS-CoV-2.